<DOC>
	<DOCNO>NCT00149292</DOCNO>
	<brief_summary>Assess efficacy new drug ( receptor agonist modulates glutamatergic activity ) treatment schizophrenia . The primary objective study determine mGlu2/3 agonist dose 28 day superior placebo treatment patient schizophrenia measure Positive Negative Symptom Scales ( PANSS ) total score .</brief_summary>
	<brief_title>Study LY2140023 Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>meet DSMIV criterion schizophrenia confirm modified SCID meet full syndromal criterion Axis I disorder take depot antipsychotic within 4 week screen take moodstabilizing agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>